Date | Price Target | Rating | Analyst |
---|---|---|---|
10/2/2024 | $45.00 → $60.00 | Buy → Neutral | BofA Securities |
8/12/2024 | $40.00 | Neutral | Piper Sandler |
7/9/2024 | $41.00 | Buy | BofA Securities |
7/9/2024 | $45.00 | Buy | Stifel |
7/9/2024 | $42.00 | Overweight | JP Morgan |
7/9/2024 | $44.00 | Overweight | Morgan Stanley |
7/9/2024 | $48.00 | Buy | Longbow |
7/9/2024 | $50.00 | Buy | TD Cowen |
8-K - Tempus AI, Inc. (0001717115) (Filer)
8-K - Tempus AI, Inc. (0001717115) (Filer)
10-Q - Tempus AI, Inc. (0001717115) (Filer)
4 - Tempus AI, Inc. (0001717115) (Reporting)
4 - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Issuer)
BofA Securities downgraded Tempus AI from Buy to Neutral and set a new price target of $60.00 from $45.00 previously
Piper Sandler initiated coverage of Tempus AI with a rating of Neutral and set a new price target of $40.00
BofA Securities initiated coverage of Tempus AI with a rating of Buy and set a new price target of $41.00
SC 13D/A - Tempus AI, Inc. (0001717115) (Filed by)
SC 13G - Tempus AI, Inc. (0001717115) (Subject)
SC 13D - Tempus AI, Inc. (0001717115) (Filed by)
4 - Tempus AI, Inc. (0001717115) (Reporting)
Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the second quarter on Tuesday, August 6, 2024. The company will hold the second quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 6326328 Domestic Dial-in Number: (800) 715-9871 International Dial-in
These eleven mid-cap stocks were the best performers in the last week. Are they in your portfolio? Virtu Financial, Inc. (NASDAQ:VIRT) shares jumped 30.04% after reporting better-than-expected Q2 financial results. V.F. Corporation (NYSE:VFC) stock upped 22.38% after the company announced it entered into a Stock and Asset Purchase Agreement to sell its Supreme brand to EssilorLuxottica (OTC: ESLOF) for $1.5 billion in cash. Several analysts raised their price forecasts on VFC. New Fortress Energy Inc. (NASDAQ:NFE) shares grew 20.19% after the company announced that it achieved First LNG for its initial Fast LNG asset located offshore Altamira, Mexico. Riot Platforms Inc (NASDAQ:
U.S. stocks were mostly higher, with the Dow Jones index gaining around 550 points on Tuesday. Shares of UnitedHealth Group Incorporated (NYSE:UNH) rose sharply during Tuesday's session following a second-quarter earnings beat. The company reported adjusted EPS of $6.80, up from $6.14 a year ago, beating the consensus of $6.66, according to data from Benzinga Pro. UnitedHealth’s revenues increased nearly $6 billion (+6.4% Y/Y) to $98.86 billion, beating the consensus of $98.34 billion, led by expansion in people served domestically at Optum and UnitedHealthcare. UnitedHealth Group shares gained 5.7% to $544.96 on Tuesday. Here are some other big stocks recording gains in today’s
Available Today for Life Science Research Use OnlyTempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced that its multimodal immune profile score (IPS) algorithmic test is now available for research use only (RUO). IPS is the first offering of a larger immunotherapy-based portfolio being developed at Tempus to bring next-generation algorithmic diagnostics to the immuno-oncology space. Additionally, Tempus is collaborating with other partners, like Cleveland Clinic, to bring additional immunotherapy-focused algorithmic tests to this growing portfolio, leveraging clinical, laboratory, genomic, and transcriptomic data to identify patients that
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announces an expansion to its collaboration with Takeda (NYSE:TAK) that takes a data-first approach to research and development, with the aim of enhancing Takeda's oncology research and development efforts. After an initial collaboration that leveraged Tempus' de-identified multimodal datasets, this new agreement will expand upon that work. Takeda will combine Tempus' multimodal real-world datasets and Tempus' biological modeling capabilities to advance Takeda's pipeline of cancer therapeutics, which includes antibody-drug conjugates (ADCs), small molecules, b
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced four abstracts were accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2024, which convenes in Barcelona, Spain, from September 13-17, 2024. "ESMO provides a great platform to share our recent research and advancements with the global oncology community, foster further collaboration, and drive forward the mission of improving patient outcomes," said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. "At Tempus, we are committed to leveraging AI and data to transform cancer care and research, and this is a
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the beta launch of a patient-facing app, olivia, an AI-enabled personal health concierge to empower individuals to holistically organize, manage, and proactively take control of their own health data. olivia, which is currently only available to beta users, leverages generative AI to provide patients and their caregivers personal, concierge-style support in managing their health. The app has a suite of features that aggregate and structure an individual's personal health information in one cohesive place, help a user track symptoms, prepare for doctor